These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 23458443

  • 1. New proteoliposome vaccine formulation from N. meningitidis serogroup B, without aluminum hydroxide, retains its antimeningococcal protectogenic potential as well as Th-1 adjuvant capacity.
    Tamargo B, Márquez Y, Ramírez W, Cedré B, Fresno M, Sierra G.
    BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S12. PubMed ID: 23458443
    [Abstract] [Full Text] [Related]

  • 2. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M, Yero D, Niebla O, González S, Climent Y, Pérez Y, Cobas K, Caballero E, García D, Pajón R.
    Vaccine; 2007 Dec 05; 25(50):8420-31. PubMed ID: 17996338
    [Abstract] [Full Text] [Related]

  • 3. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.
    Fransen F, Boog CJ, van Putten JP, van der Ley P.
    Infect Immun; 2007 Dec 05; 75(12):5939-46. PubMed ID: 17908810
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO, Dias WO, Schenkman RP, Raw I, Tanizaki MM.
    FEMS Immunol Med Microbiol; 2004 Jul 01; 41(3):205-10. PubMed ID: 15196569
    [Abstract] [Full Text] [Related]

  • 5. Pilot scale production of the vaccine adjuvant Proteoliposome derived Cochleates (AFCo1) from Neisseria meningitidis serogroup B.
    Zayas C, González D, Acevedo R, del Campo J, Lastre M, González E, Romeu B, Cuello M, Balboa J, Cabrera O, Guilherme L, Pérez O.
    BMC Immunol; 2013 Jul 01; 14 Suppl 1(Suppl 1):S4. PubMed ID: 23458578
    [Abstract] [Full Text] [Related]

  • 6. New vaccines require potent adjuvants like AFPL1 and AFCo1.
    Pérez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M, Balboa J, Acevedo R, Zayas C, Gil D, Mora N, González D, Pérez R, González E, Barberá R, Fajardo EM, Sierra G, Solís RL, Campa C.
    Scand J Immunol; 2007 Jul 01; 66(2-3):271-7. PubMed ID: 17635804
    [Abstract] [Full Text] [Related]

  • 7. Hybrid response to SARS-CoV-2 and Neisseria meningitidis C after an OMV-adjuvanted immunization in mice and their offspring.
    Portilho AI, Hermes Monteiro da Costa H, Grando Guereschi M, Prudencio CR, De Gaspari E.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2346963. PubMed ID: 38745461
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of immunological responses to recombinant Porin A protein (rPoA) from native strains of Neisseria meningitidis serogroups A and B using OMV as an adjuvant in BALB/c mice.
    Afrough P, Bouzari S, Mousavi SF, Asadi Karam MR, Vaziri F, Fateh A, Behrouzi A, Malekan M, Siadat SD.
    Microb Pathog; 2017 Nov 31; 112():209-214. PubMed ID: 28942175
    [Abstract] [Full Text] [Related]

  • 9. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
    Holst J.
    Hum Vaccin; 2007 Nov 31; 3(6):290-4. PubMed ID: 17712231
    [Abstract] [Full Text] [Related]

  • 10. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
    Pajon R, Buckwalter CM, Johswich KO, Gray-Owen SD, Granoff DM.
    Vaccine; 2015 Mar 10; 33(11):1317-1323. PubMed ID: 25662856
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.
    Ochoa-Azze RF, García-Imía L, Vérez-Bencomo V.
    MEDICC Rev; 2018 Jul 10; 20(3):22-29. PubMed ID: 31242158
    [Abstract] [Full Text] [Related]

  • 12. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H, Feavers IM.
    Expert Rev Vaccines; 2011 Mar 10; 10(3):323-34. PubMed ID: 21434800
    [Abstract] [Full Text] [Related]

  • 13. AFCo1 as nasal adjuvant of capsular polysaccharide from Neisseria meningitidis serogroup C induces systemic and mucosal immune responses.
    Romeu B, González E, Zayas C, Del Campo J, Acevedo R, Cuello M, Valdes Y, Balboa J, Cabrera O, Lastre M, Pérez O.
    Scand J Infect Dis; 2011 Oct 10; 43(10):809-13. PubMed ID: 21671827
    [Abstract] [Full Text] [Related]

  • 14. Immune responses of a meningococcal A + W outer membrane vesicle (OMV) vaccine with and without aluminium hydroxide adjuvant in two different mouse strains.
    Tunheim G, Arnemo M, Naess LM, Norheim G, Garcia L, Cardoso D, Mandiarote A, Gonzalez D, Sinnadurai K, Fjeldheim ÅK, Bolstad K, Rosenqvist E.
    APMIS; 2016 Nov 10; 124(11):996-1003. PubMed ID: 27651089
    [Abstract] [Full Text] [Related]

  • 15. Human antibody and memory B and T-cell responses after primary and booster immunisation against Neisseria meningitidis B.
    Cruz SC, Souza SL, Cruz AC, Silva GP, Milagres LG.
    Vaccine; 2011 Oct 06; 29(43):7387-94. PubMed ID: 21803107
    [Abstract] [Full Text] [Related]

  • 16. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa.
    Acevedo R, Zayas C, Norheim G, Fernández S, Cedré B, Aranguren Y, Cuello M, Rodriguez Y, González H, Mandiarote A, Pérez M, Hernández M, Hernández-Cedeño M, González D, Brorson SH, Rosenqvist E, Naess L, Tunheim G, Cardoso D, García L.
    Pharmacol Res; 2017 Jul 06; 121():194-201. PubMed ID: 28495657
    [Abstract] [Full Text] [Related]

  • 17. A putative amino acid ABC transporter substrate-binding protein, NMB1612, from Neisseria meningitidis, induces murine bactericidal antibodies against meningococci expressing heterologous NMB1612 proteins.
    Hung MC, Humbert MV, Laver JR, Phillips R, Heckels JE, Christodoulides M.
    Vaccine; 2015 Aug 26; 33(36):4486-94. PubMed ID: 26207592
    [Abstract] [Full Text] [Related]

  • 18. Recombinant outer membrane secretin PilQ(406-770) as a vaccine candidate for serogroup B Neisseria meningitidis.
    Haghi F, Peerayeh SN, Siadat SD, Zeighami H.
    Vaccine; 2012 Feb 21; 30(9):1710-4. PubMed ID: 22234267
    [Abstract] [Full Text] [Related]

  • 19. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
    Matthias KA, Reveille A, Connolly KL, Jerse AE, Gao YS, Bash MC.
    Vaccine; 2020 Feb 28; 38(10):2396-2405. PubMed ID: 32037226
    [Abstract] [Full Text] [Related]

  • 20. Remote induction of cellular immune response in mice by anti-meningococcal nanocochleates - nanoproteoliposomes.
    Tamargo Santos B, Fleitas Pérez C, Infante Bourzac JF, Márquez Nápoles Y, Ramírez González W, Bourg V, Torralba D, Pérez V, Mouriño A, Ayala J, Labrada Rosado A, Aleya L, Bungau S, Sierra González VG.
    Sci Total Environ; 2019 Jun 10; 668():1055-1063. PubMed ID: 31018447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.